Uniphar PLC is primarily active in the healthcare and pharmaceutical industries.

The main competitors of Uniphar PLC in the market include companies like McKesson, AmerisourceBergen, and Cardinal Health. These companies operate in the same industry as Uniphar, providing pharmaceutical and healthcare distribution services. Other competitors that Uniphar faces in specific segments of its business include Sisk Healthcare, United Drug, and DCC Healthcare. Uniphar PLC competes with these industry players to gain market share and maintain its position in the healthcare and pharmaceutical distribution sector.

Uniphar PLC is a leading healthcare services provider based in Ireland. Established in 1967, the company has a rich history of over 50 years. Initially a wholesale pharmaceutical business, Uniphar expanded its operations to include integrated commercial and clinical services. Today, it offers a comprehensive range of services to the healthcare industry, including supply chain management, retail pharmacy, product licensing, and support services. Uniphar has a strong presence in Ireland and the UK, and its diverse customer base includes hospitals, pharmacies, pharmaceutical manufacturers, and the government. The company's commitment to innovation, reliability, and customer satisfaction has propelled it to become a trusted partner in the healthcare sector.

Some significant milestones achieved by Uniphar PLC include its successful listing on the Euronext Dublin and London Stock Exchanges in July 2019, marking a significant step in its growth and expansion plans. The company has also made strategic acquisitions, such as the acquisition of M3 Medical Limited in 2020, which strengthened its position in the Irish healthcare market. Furthermore, Uniphar PLC has consistently delivered strong financial performance, with revenue and profit growth year after year. Its focus on innovation and developing new capabilities has allowed the company to enhance its offering and provide comprehensive solutions to the healthcare industry.

Uniphar PLC is primarily present in Ireland, the United Kingdom, and the Benelux region. This pharmaceutical and healthcare services company operates across these countries, providing a wide range of services to healthcare providers, manufacturers, and patients. Uniphar PLC's strong presence in these regions allows them to leverage their expertise and network for the benefit of their customers.

Uniphar PLC represents values of integrity, collaboration, innovation, and customer-focus. With a strong corporate philosophy centered around delivering excellence in healthcare, Uniphar is committed to providing high-quality products and services to improve patient outcomes. The company places great emphasis on building trusted partnerships with healthcare professionals and industry stakeholders, enabling them to navigate complex healthcare supply chains effectively. Uniphar's dedication to continuous innovation and adaptability in a rapidly evolving industry sets it apart. By prioritizing customer needs and maintaining a steadfast focus on ethical practices, Uniphar PLC has established itself as a leading player in the healthcare sector.

Analysts currently set an average price target of 4.93 EUR for the Uniphar stock (median: 4.94 EUR), implying +18.0 % versus the latest price. The consensus is based on 12 analyst ratings.

Uniphar Analyst Price Targets 2026

12 analysts currently rate the Uniphar stock: 11 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Uniphar to generate revenue of 3.21 B EUR and earnings per share of 0.28 EUR.

Uniphar Analyst Price Targets 2026

The Uniphar share (UPR.IR) is listed on 4 stock exchanges, including: Frankfurt (0NR.F), München (0NR.MU), London (UPR.L), London (UPR.L).

Uniphar PLC is a leading provider of healthcare solutions and pharmaceutical products in Europe. The company offers a wide range of services and products that meet the medical needs of patients. Uniphar was founded in 1994 and has been a publicly listed company since 2019. The business model of Uniphar is focused on offering a comprehensive range of services and products in various areas of healthcare. The company has different divisions tailored to the needs of its customers. The division "Uniphar Retail Services" specializes in wholesale and retail. The division offers a wide range of retail products, including over-the-counter medications, dietary supplements, medical devices, and cosmetics. Uniphar also works closely with retailers to develop customized solutions for their needs. Uniphar also has a division called "Uniphar Group" that specializes in providing pharmaceutical products to hospitals and clinics. In addition, the division also offers solutions for drug manufacturing and delivery. Through close collaboration with the pharmaceutical industry, the company also offers solutions for the trade of pharmaceutical products. The division "Uniphar Specialty Healthcare" specializes in the distribution of specialized drugs. The company offers a wide range of medical products for the treatment of chronic conditions such as diabetes, cancer, and HIV/AIDS. The division also works closely with healthcare professionals and hospitals to ensure that patients receive the right medications. Uniphar has also developed a digital platform called "Uniphar Connect". This platform allows customers and business partners to access a wide range of products and services offered by Uniphar. The platform also provides efficient order and delivery processing to ensure that customers receive their required products quickly and easily. Overall, Uniphar has a diversified product portfolio and offers a comprehensive range of services tailored to the needs of the healthcare industry. The company has a strong presence in Europe and works closely with its customers and partners to develop customized solutions for their needs. With a strong focus on digital innovation and strategic partnerships, the company is well positioned to be successful in the future.

The expected revenue of Uniphar is 3.21 B EUR. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Uniphar is 71.48 M EUR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Uniphar is currently 15.27. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Uniphar stock.

The price-to-sales ratio (P/S) of Uniphar is currently 0.34. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Uniphar stock.

The Eulerpool Quality Score for Uniphar is 6/10.

The ISIN of Uniphar is IE00BJ5FQX74. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Uniphar is A2PNWJ. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Uniphar is UPR.IR. The ticker symbol is used to trade Uniphar shares on the stock exchange.

Over the past 12 months, Uniphar paid a dividend of 0.02 EUR . This corresponds to a dividend yield of about 0.47 %. For the coming 12 months, Uniphar is expected to pay a dividend of 0.03 EUR.

The current dividend yield of Uniphar is 0.47 %.

Uniphar pays a dividend, distributed in the months of , , , .

Uniphar paid dividends every year for the past 6 years.

For the upcoming 12 months, dividends amounting to 0.03 EUR are expected. This corresponds to a dividend yield of 0.68 %.

Uniphar is assigned to the 'Health' sector.

To receive the latest dividend of Uniphar from amounting to 0.01 EUR, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, Uniphar distributed 0.02 EUR as dividends.

The dividends of Uniphar are distributed in EUR.